Looking for Steady Passive Income? This S&P 500 Dividend Stock Pays You Monthly.

Healthpeak Properties reported Q1 EPS of $0.28, four times the $0.06 forecast, while $739 million of revenue exceeded the $687 million consensus by 7.5%; shares have risen 27.5% in 2026. Management raised full-year FFO guidance twice, most recently to $1.73-$1.77 per share following strong Q2 results. The healthcare REIT offers a $1.22 annual dividend, equating to roughly a 6% yield at $20.42, supported by aging-population demand for healthcare and senior housing, though higher interest rates remain a material REIT risk.

Analysis

DOC now trades near 11.7x the midpoint of implied annual FFO, leaving a plausible path to roughly $23 if investors grant a 13x multiple; that is a valuation rerating trade, not merely a dividend-yield trade. The key question is whether the guidance increase reflects durable same-store NOI and occupancy improvement rather than one-time items, asset sales, or lower-than-expected interest expense. Verify leasing spreads, life-science exposure, and the debt-maturity schedule before treating the higher run-rate as recurring.

The immediate catalyst window is the next earnings release and any decline in the 10-year Treasury yield: healthcare-property cash flows can re-rate quickly as investors rotate from cash and bonds back into income equities. Over 6-18 months, outpatient migration and healthcare utilization should favor DOC relative to office REITs such as BXP and VNO, but senior-housing-oriented WELL and VTR may capture more direct demographic upside if labor costs normalize. DOC's relative advantage is defensive healthcare tenancy; its relative weakness is that medical-office leasing can still be pressured by provider consolidation and health-system capital-budget restraint.

Consensus appears to be treating the yield as the thesis, while the more important risk is duration: a 50-75 bp upward move in long yields can erase a full year of dividend carry through multiple compression. The rally is therefore vulnerable if FFO growth stalls near the low end of guidance or if refinancing costs rise faster than lease escalators. A break below the midpoint of the current FFO outlook, deteriorating occupancy, or a material increase in floating-rate interest expense would falsify the bullish case.

Key Decisions for Investors

• Initiate a modest DOC long only on a pullback toward $19.50-$20.00 or after confirmation that quarterly FFO remains on a $1.75+ annualized run-rate; base case is $22.50-$23.00 over 3-6 months plus carry, with a stop/reassessment below $18.25 or on guidance below $1.73.
• For a rate-hedged expression, pair long DOC against short VNQ or a Treasury-duration hedge rather than treating the 6% yield as unhedged income. The thesis is DOC-specific operational execution; reduce the position if 10-year yields rise materially without corresponding upward revisions to FFO.
• Watch DOC versus WELL/VTR after the next reporting cycle: favor DOC only if medical-office occupancy and same-store NOI accelerate. If senior-housing RevPOR and margins improve faster than DOC leasing metrics, rotate the healthcare-REIT allocation toward WELL or VTR.
• Do not chase the post-results move with upside calls until debt maturities, fixed-versus-floating exposure, and normalized interest expense are verified; those missing inputs determine whether the apparent FFO beat supports a durable multiple expansion.